Sugi Predict

Sugi Predict / Targets / FCGR2A

FCGR2A

Low affinity immunoglobulin gamma Fc region receptor II-a · P12318 · FCGR2A on Sugi Atlas →

334 patent compounds predicted against FCGR2A, 250 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13917176 SCHEMBL13917176 1.00 1/20
SCHEMBL13421296 SCHEMBL13421296 0.96 1/20
SCHEMBL13917185 SCHEMBL13917185 0.89 1/20
SCHEMBL13921798 SCHEMBL13921798 0.84 1/20
SCHEMBL13420987 SCHEMBL13420987 0.82 1/20
SCHEMBL13420936 SCHEMBL13420936 0.82 1/20
SCHEMBL13421092 SCHEMBL13421092 0.81 1/20
SCHEMBL13917179 SCHEMBL13917179 0.81 1/20
SCHEMBL13421360 SCHEMBL13421360 0.81 1/20
SCHEMBL13421062 SCHEMBL13421062 0.80 1/20
SCHEMBL13917183 SCHEMBL13917183 0.80 1/20
SCHEMBL13917186 SCHEMBL13917186 0.80 1/20
SCHEMBL13917188 SCHEMBL13917188 0.80 1/20
SCHEMBL3200004 SCHEMBL3200004 0.80 1/20
SCHEMBL13921832 SCHEMBL13921832 0.80 1/20
SCHEMBL13420995 SCHEMBL13420995 0.79 1/20
SCHEMBL13921837 SCHEMBL13921837 0.78 1/20
SCHEMBL13421038 SCHEMBL13421038 0.78 1/20
SCHEMBL13921814 SCHEMBL13921814 0.77 1/20
SCHEMBL13421029 SCHEMBL13421029 0.77 1/20

Clinical trials — most relevant to FCGR2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) PHASE4COMPLETED
The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma PHASE4COMPLETED
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients PHASE2/PHASE3COMPLETED
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Allergic Rhinitis, Immunotherapy and Vitamin d PHASE2/PHASE3UNKNOWN
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma PHASE2COMPLETED
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma PHASE2COMPLETED
Effect of Anti-IgE in Chronic Urticaria PHASE2COMPLETED
Rituximab in the Treatment of Graves' Disease PHASE1/PHASE2COMPLETED
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide PHASE1/PHASE2COMPLETED
Post IVIG Medication in Children With Immune Thrombocytopenia PHASE1UNKNOWN
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma PHASE1ACTIVE_NOT_RECRUITING
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma PHASE1COMPLETED
Preventive IVIG Therapy for Congenital Heart Block EARLY_PHASE1COMPLETED
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis. nanRECRUITING
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit nanUNKNOWN
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus nanCOMPLETED
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer nanRECRUITING
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? nanUNKNOWN
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation nanCOMPLETED
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation nanCOMPLETED
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact nanRECRUITING
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy nanCOMPLETED
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet nanUNKNOWN
Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab nanCOMPLETED
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FCGR2A binder may also engage these)

ProteinNameSimilarity
Q8SPV8 — 1.000 Q8SPV8 →
P31995 — 1.000 P31995 →
Q60513 — 0.995 Q60513 →
P31994 — 0.990 P31994 →
Q63203 — 0.989 Q63203 →
P08101 — 0.989 P08101 →
P27645 — 0.987 P27645 →
D3ZQX2 — 0.986 D3ZQX2 →
Q8SPW2 — 0.986 Q8SPW2 →
Q09TM2 — 0.986 Q09TM2 →
P08637 — 0.985 P08637 →
P12319 — 0.984 P12319 →
Q09TM4 — 0.984 Q09TM4 →
Q8BG84 — 0.984 Q8BG84 →
E2RP87 — 0.983 E2RP87 →
A3RFZ7 — 0.983 A3RFZ7 →
Q68SN8 — 0.983 Q68SN8 →
P26151 — 0.982 P26151 →
Q9N2I5 — 0.982 Q9N2I5 →
P0DTI4 — 0.982 P0DTI4 →
P08508 — 0.981 P08508 →
Q64281 — 0.981 Q64281 →
Q9ET39 — 0.981 Q9ET39 →
Q61450 — 0.981 Q61450 →
H0VDZ8 — 0.981 H0VDZ8 →
P43628 — 0.981 P43628 →
Q92637 — 0.980 Q92637 →
Q13291 — 0.980 Q13291 →
A0A0B4J1G0 — 0.979 A0A0B4J1G0 →
P83555 — 0.979 P83555 →